Papers/PMID:28556498
Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Annals of neurology2017The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
sodium(1+) — no detected effect on expanded Disability Status Scale (EDSS)
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Average 24-hour urine sodium levels were not associated with conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] = 0.91, 95% confidence interval [CI] = 0.67-1.24 per 1g increase in estimated daily sodium intake), nor were they associated with clinical or MRI outcomes (new active lesions after 6 months: HR = 1.05, 95% CI = 0.97-1.13; relative change in T2 lesion volume: -0.11, 95% CI = -0.25 to 0.04; change in EDSS: -0.01, 95% CI = -0.09 to 0.08; relapse rate: HR = 0.78, 95% CI = 0.56-1.07).”
Quoted verbatim from Sodium intake and multiple sclerosis activity and progression in BENEFIT.. - Study
- cohort
- Population
- 465 patients with a clinically isolated syndrome in the BENEFIT trial; exposure is estimated 24-hour urine sodium (Tanaka equations) from repeated spot urines, per 1 g increase, not an assigned dose
Sodium intake and multiple sclerosis activity and progression in BENEFIT.2017PMID:28556498Permalink